204 EVALUATION OF MALE SLING AND HEALTH RELATED QUALITY OF LIFE FOR STRESS URINARY INCONTINENCE: ARE THE LONG TERM RESULTS MAINTAINED?

2007 ◽  
Vol 6 (2) ◽  
pp. 73 ◽  
Author(s):  
C. D'Ancona ◽  
R. Reges ◽  
P. Palma ◽  
C. Riccetto ◽  
N.R. Netto
2016 ◽  
pp. 21-25
Author(s):  
Athanasios Farfaras ◽  
Stefanos Antoniou ◽  
Panagiotis Skolarikos

Introduction: Stress urinary incontinence represents a common but strongly underestimated health problem that affects women of all ages and severely downgrades their health related quality of life. The transobturator vaginal tape (TVT-O) approach offers long term success rates, while minimizing complications. In this study, we examined quality of life of patients suffering by stress urinary incontinence and investigated whether TVT-O procedure offers considerable benefits in patient’s quality of life after 5 years of placement. Methods and results: Women with confirmed urodynamic stress urinary incontinence that underwent TVT-O procedure were included in this prospective study. Patient’s quality of life was evaluated by using the Greek version of SF-36 preoperatively and 60 months postoperatively. The outcomes demonstrated that incontinence had significant adverse effect in patient’s quality of life. However, TVT-O procedure offers a safe and efficient treatment, substantially improving both physical and mental dimension of women’s health related quality of life (P>0.05). Discussion: Stress urinary incontinence strongly impairs women’s health related quality of life, limiting their physical activities, social function and causing emotionally imbalance. Insertion of tension free vaginal tape reverses symptoms and significantly improves all health indicators associated with patient’s health related quality of life. In our study, we demonstrate that minimal invasive surgery, by using TVT-O procedure is highly effective, in long term, in improving quality of life of women with stress urinary incontinence.


2008 ◽  
Vol 134 (4) ◽  
pp. A-863
Author(s):  
Marco Scarpa ◽  
Duilio Pagano ◽  
Cesare Ruffolo ◽  
Anna Pozza ◽  
Francesa Erroi ◽  
...  

2007 ◽  
Vol 25 (36) ◽  
pp. 5723-5730 ◽  
Author(s):  
Martin J.B. Taphoorn ◽  
Martin J. van den Bent ◽  
Murielle E.L. Mauer ◽  
Corneel Coens ◽  
Jean-Yves Delattre ◽  
...  

Purpose Little is known about the health-related quality of life (HRQOL) of patients treated for anaplastic oligodendrogliomas. The impact of combined procarbazine, CCNU (lomustine), and vincristine (PCV) chemotherapy after radiotherapy (RT) compared with RT alone on HRQOL in the randomized European Organisation for Research and Treatment of Cancer (EORTC) 26951 trial was studied. Patients and Methods Adult patients with anaplastic oligodendrogliomas received RT alone or RT plus PCV chemotherapy. HRQOL was assessed with the EORTC Quality of Life Questionnaire C30 and Brain Cancer Module. Seven prespecified HRQOL end points were selected. We hypothesized that chemotherapy would impair HRQOL during treatment but that there would be a similar HRQOL between treatment arms once off treatment. Assessments were performed at randomization, at the end of RT, and then every 3 to 6 months until progression. Results A total of 368 patients were randomly assigned to one of the two arms; overall, 58% were male, and the median age was 49 years. Compliance with HRQOL was 78% at baseline and dropped to 55% to 72% up to 2.5 years post-RT. Baseline scores demonstrated considerable impairments in HRQOL for both treatment groups. The longitudinal analysis showed a significant increase in nausea/vomiting in the RT plus PCV chemotherapy arm during and shortly after chemotherapy. Because of a difference in baseline scores for fatigue and physical functioning, the differences between treatment arms during PCV did not reach significance. The nonselected scales of appetite loss and drowsiness demonstrated significant differences between treatment arms during chemotherapy in favor of the RT arm. The long-term results showed no difference between arms. Conclusion The major impact of PCV on HRQOL is on nausea/vomiting, loss of appetite, and drowsiness during and shortly after treatment. There are no long-term effects of PCV chemotherapy.


2018 ◽  
Vol 20 (suppl_3) ◽  
pp. iii318-iii318
Author(s):  
A H Zamanipoor Najafabadi ◽  
P B van der Meer ◽  
F W Boele ◽  
J C Reijneveld ◽  
M J B Taphoorn ◽  
...  

2008 ◽  
Vol 13 (1) ◽  
pp. 105-112 ◽  
Author(s):  
Marco Scarpa ◽  
Duilio Pagano ◽  
Cesare Ruffolo ◽  
Anna Pozza ◽  
Lino Polese ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document